Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients

Transplant Infectious Disease

Volumn 14, Issue 6, 2012, Pages 626-634

  Ha, Y E ^a   Joo, E J ^a   Park, S Y ^a   Wi, Y M ^a   Kang, C I ^a   Chung, D R ^a   Joh, J W ^a   Lee, S K ^a   Song, J H ^a   Peck, K R ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cytomegalovirus; Rifampicin; Solid organ transplantation; Tacrolimus; Tuberculosis

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSERINE; CYCLOSPORIN; DACLIZUMAB; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; KOREAN MEDICINE; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AGED; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RIFAMPIN; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84870990153     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00721.x     Document Type: Article

References (32)

1. Subramanian A, Dorman S. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S57-S62.
2. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48 (9): 1276-1284.
3. World Health Organization (WHO). Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva: WHO, 2008. Available at: http://www.who.int/tb/publications/global_report/2008/pdf/fullreport.pdf. Accessed 11 December 2010.
4. Shim TS, Koh WJ, Yim JJ, Lew WJ. Diagnosis and treatment of latent tuberculosis infection in Korea. Tuberc Respir Dis 2004; 57 (2): 101-108.
5. Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007; 22 (5): 779-783.
6. Ernster VL. Nested case-control studies. Prev Med 1994; 23 (5): 587-590.
7. World Health Organization (WHO). TB Country Profile of Republic of Korea: Surveillance and Epidemiology. Geneva: WHO, 2010. Available at: https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=KR&outtype=html. Accessed 11 December 2010.
8. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48 (12): 1657-1665.
9. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40 (4): 581-587.
10. Centers for Disease Control and Prevention. Transplantation-transmitted tuberculosis-Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep 2008; 57 (13): 333-336.
11. Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am 2010; 24 (2): 497-514.
12. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27 (5): 1266-1277.
13. Basiri A, Hosseini-Moghaddam SM, Simforoosh N, et al. The risk factors and laboratory diagnostics for post renal transplant tuberculosis: a case-control, country-wide study on definitive cases. Transpl Infect Dis 2008; 10 (4): 231-235.
14. Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis 2010; 12 (2): 106-112.
15. Tharayil John G, Shankar V, Talaulikar G, et al. Epidemiology of systemic mycoses among renal-transplant recipients in India. Transplantation 2003; 75 (9): 1544-1551.
16. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63 (12): 1247-1297.
17. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5 (2): 84-93.
18. Penninga L, Moller CH, Gustafsson F, Steinbruchel DA, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 2010; 66 (12): 1177-1187.
19. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200 (6): 1002-1011.
20. Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195 (5): 756-764.
21. Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008; 52 (2): 735-738.
22. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22 (6): 920-925.
23. Cassidy MJ, Van Zyl-Smit R, Pascoe MD, Swanepoel CR, Jacobson JE. Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient. Nephron 1985; 41 (2): 207-208.
24. Offermann G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5 (5): 385-387.
25. Allen RD, Hunnisett AG, Morris PJ. Cyclosporin and rifampicin in renal transplantation. Lancet 1985; 1 (8435): 980.
26. Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant Proc 2003; 35 (7): 2449-2451.
27. Geary DF, Thorner P, Baumal R, Major M, Arbus G. Cyclosporin A in children with persistent renal transplant rejection and progressively deteriorating graft function. Pediatr Nephrol 1987; 1 (2): 140-144.
28. Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39 (3): 313-314.
29. Van Buren D, Wideman CA, Ried M, et al. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc 1984; 16 (6): 1642-1645.
30. Yehia BR, Blumberg EA. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl 2010; 16 (10): 1129-1135.
31. Al-Sulaiman MH, Dhar JM, Al-Khader AA. Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine. Transplantation 1990; 50 (4): 597-598.
32. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections. Tuberculosis. Nephrol Dial Transplant 2002; 17 (Suppl 4): 39-43.